日本神経精神薬理学会, JSNP Excellent Presentation Award for AsCNP,The ubiquitination of serotonin transporter in lymphoblasts derived from fluvoxamine-resistant depression patients
Indoleamine 2,3-dioxygenase 2 (IDO2) is an enzyme of the tryptophan-kynurenine pathway that is constitutively expressed in the brain. To provide insight into the physiological role of IDO2 in the brain, behavioral and neurochemical analyses in IDO...
Chronic orofacial pain (COP) is relieved by duloxetine (DLX) and frequently causes depressive symptoms. The aim of this study was to confirm effects of DLX on pain and depressive symptoms, and to associate with their effectiveness in pl...
British journal of pharmacology 180(18) 2393-2411 2023年4月
BACKGROUND AND PURPOSE: High salt (HS) intake has been associated with hypertension and cognitive impairment. It is well-known that angiotensin II (Ang II)-AT1 and prostaglandin E2 (PGE2)-EP1 systems are involved in hypertension and neurotoxicity....
Major depressive disorder (MDD) is a common mental disorder characterized by reduced motivation, diminished interest and pleasure, and anhedonia. We have proposed melanoma-associated antigen D1 (MAGE-D1) knock out (KO) mouse is a MDD model, and wh...
White matter abnormalities have been implicated in psychiatric diseases such as major depressive disorder (MDD) ; however, the underlying mechanisms remain poorly understood. The structure and function of the corpus callosum are particularly vulne...
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by social deficit and stereotyped, repetitive patterns of behaviors and interests. Maternal use of valproic acid (VPA) during pregnancy is associated with an inc...
Major depressive disorder (MDD) is a worldwide serious psychiatric disease, and more than 300 million people suffer from MDD. Chronic stress contributes to the pathogenesis of MDD. Cigarette smoking is strongly associated with MDD. Epidemiological...
Chronic stress contributes to the pathogenesis of major depressive disorder (MDD). The efficacy of ketamine on the treatment-resistant MDD implies the involvement of glutamatergic dysregulation in its pathophysiology. We recently demonstrated the ...